Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.01 -0.39 (-0.25%)
Official Closing Price Updated: 5:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Johnson & Johnson Secures Complete FDA Approval For Bladder Cancer Drug Balversa, After Almost Five Years Of Accelerated Approval
FDA-approved Balversa for urothelial carcinoma treatment. The first oral FGFR kinase inhibitor offers clinical benefits, extended overall survival, and a breakthrough for FGFR alterations in metastatic... 
Via Benzinga
Exposures Product Safety
Johnson & Johnson's Q4 Earnings: Spotlight On Dividend Security Following Kenvue Split, Legal Costs, Acquisitions
Johnson & Johnson (JNJ) to report Q4 earnings on Jan. 23, with expectations of $2.28 EPS and $20.99B revenue. Strong, diverse company with reliable dividend, but impacted by talc lawsuit settlement and... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
3 undervalued stocks: Is now the right time to buy?
WK Kellogg, Newmont, and WEC Energy Group have upside potential as undervalued stocks, although each is navigating challenges that pushed valuations lower. 
Via MarketBeat
How Is The Market Feeling About Johnson & Johnson?
Via Benzinga
3 Dividend Stocks For A Steady Drip Of Income
Dividend Reinvestment Plans allow investors to unleash the power of compounding dividends. 
Via Talk Markets
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Tesla, Netflix, Intel Take Center Stage In Pivotal Q4 Earnings Week As S&P 500 Eyes Breaking New Highs
According to Factset, the fourth-quarter earnings season has had a weak start, with the percentage of S&P 500 companies reporting positive earnings surprises below average. 
Via Benzinga
Topics Stocks
Exposures US Equities
I'm Putting My Cash Stockpile to Work on These 3 Stocks
With the market selling off to start the year, this Fool plans to put some of his growing cash pile to work. 
Via The Motley Fool
Nearing Retirement? These Stocks Are as Safe as They Come
These stocks should provide solid income with little drama. 
Via The Motley Fool
Walgreens Boots Alliance Just Cut Its Dividend: Here Are 2 Companies That Won't
Not every dividend stock is created equal, and these two far exceed Walgreens Boots Alliance. 
Via The Motley Fool
My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024
These stocks may help you win in 2024 -- no matter what the market does. 
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More in 2024
These big winners could keep the momentum going. 
Via The Motley Fool
Q4 Earnings Results Reflect Stability
We get into the heart of the Q4 earnings season this week, with more than 225 companies reporting results, including 71 S&P 500 members from various sectors and industries 
Via Talk Markets
Topics Stocks
Exposures US Equities
3 Reasons to Rely on Dividend Stocks
Dividend stocks can be a great hedge against volatile while still providing powerful returns via compounding. 
Via InvestorPlace
7 Must-Have Stocks for Serious Wealth Accumulation
Unlock the strategies of seven finance and commerce stalwarts on the path to serious wealth accumulation and industry leadership. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
The 3 Most Undervalued Value Stocks to Buy in January
With so many investments turning in a surprisingly robust performance last year, it’s time to consider undervalued value stocks. 
Via InvestorPlace
4 Fantastic Dividend King Stocks to Buy in 2024
All four of these companies have been increasing their dividend payouts for over 50 years. 
Via The Motley Fool
Hidden High-Yielders: 7 Overlooked Stocks with Attractive Dividends
Here are seven overlooked high-yield dividend stocks for you to consider no matter where interest rates at the end of 2024. 
Via InvestorPlace
2 Former Warren Buffett Stocks That Stand Out as Stong Buys in 2024
Berkshire Hathaway exited its positions in these two blue chip dividend stocks last year, but they are still superb buys for certain types of investors. 
Via The Motley Fool
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will... 
Via Talk Markets
2 Average Stocks That Could Make You Rich
You don't always have to pick a game-changing company to win in the stock market. 
Via The Motley Fool
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. 
Via Investor's Business Daily
Topics ETFs
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. 
Via Investor's Business Daily
Dividend Dynasty: 7 High-Yield Stocks for Long-Term Wealth Accumulation
Navigate 'Dividend Dynasty': Uncover seven high-yield stocks combining stable dividends with sustainable growth strategies. 
Via InvestorPlace
Walgreens Cut Its Dividend by 48%: Here Are 5 Better Dow Dividend Stocks to Buy in January
Businesses with efficient operations and growth potential open the door to dividend raises for years to come. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Why Eli Lilly Stock Skyrocketed 59% in 2023
Lilly's pipeline success in 2023 allowed it to to claim the crown as the biggest drugmaker on the planet by market cap. 
Via The Motley Fool
2 Dow Stocks to Buy Hand Over Fist in 2024 and 1 to Avoid Like the Plague
Among the Dow Jones Industrial Average's 30 time-tested components, there are two that are historically cheap and ripe for the picking, while another outperformer is riddled with issues. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Unshakeable Dividend Stocks for Lifelong Wealth
No matter what the circumstances, passive income won’t go out of style, thus driving the case for these long-term dividend stocks. 
Via InvestorPlace
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.